AV Lopinavir
| Zeile 11: | Zeile 11: | ||
{{tp|p=32273604|t=2020. Lopinavir-ritonavir in severe COVID-19 |pdf=|usr=}} | {{tp|p=32273604|t=2020. Lopinavir-ritonavir in severe COVID-19 |pdf=|usr=}} | ||
{{tp|p=32114746|t=2020. Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer |pdf=|usr=}} | {{tp|p=32114746|t=2020. Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer |pdf=|usr=}} | ||
| + | {{tp|p=32407513|t=2020. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?|pdf=|usr=008}} | ||
| + | {{tp|p=32473230|t=2020. Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.|pdf=|usr=008}} | ||
| + | |||
| + | {{tp|p=32474026|t=2020. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?|pdf=|usr=008}} | ||
| + | {{tp|p=32422065|t=2020. Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).|pdf=|usr=008}} | ||
| + | {{tp|p=32385749|t=2020. Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.|pdf=|usr=008}} | ||
Version vom 27. Juni 2020, 21:01 Uhr
32271456 2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019
32362644 2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use
32173576 2020. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression
32331982 ä. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
32080993 2020. The Author s Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32080992 2020. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32056407 2020. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32187464 ä. A Trial of Lopinavir?Ritonavir in Adults Hospitalized with Severe Covid-19
32104907 ä. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus?A possible reference for coronavirus disease?19 treatment option
32369286 2020. A Trial of Lopinavir-Ritonavir in Covid-19 Reply
32273604 2020. Lopinavir-ritonavir in severe COVID-19
32114746 2020. Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer
32407513 2020. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
32473230 2020. Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.
32474026 2020. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
32422065 2020. Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).
32385749 2020. Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.
